Neuro oncology News and Research

RSS

Celldex’s lead program RINTEGA demonstrates overall survival benefit in patients with recurrent glioblastoma

Celldex Therapeutics, Inc. today presented positive results from the Company’s randomized, double‐blind Phase 2 study of RINTEGA (rindopepimut) in patients with EGFRvIII‐positive, recurrent glioblastoma at the 2015 American Society of Clinical Oncology in Chicago.

2 Jun 2015

VBL Therapeutics reports positive results from VB-111 Phase 1/2a study in recurrent platinum-resistant Müllerian cancer

VBL Therapeutics, a late-stage clinical biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced positive interim results from an investigator-initiated, Phase 1/2a trial of multiple dose VB-111 in recurrent platinum-resistant Müllerian (ovarian) cancer.

2 Jun 2015

Caris Molecular Intelligence allows comparisons between tumors sharing histological features

Caris Life Sciences, a leading biotechnology company focused on fulfilling the promise of precision medicine, today announced the presentation of data from three studies that demonstrate the utility of Caris Molecular Intelligence®, the company's panomic comprehensive tumor profiling service, in facilitating comparisons between tumors that share histological features.

1 Jun 2015

Researchers identify key driver mutations in glioma samples that confirm tumor heterogeneity

Caris Life Sciences today announced the presentation of data from a study in which researchers identified biomarker changes, including key driver mutations, in 89% of metachronous paired glioma tumors, indicating changes in response to therapy as the disease progresses.

1 Jun 2015

Researchers identify chemical pathway associated with seizures, shorter survival in patients with malignant glioma

Researchers at the University of Alabama at Birmingham have identified a chemical pathway that may be associated with seizures and shorter patient survival in some patients with malignant glioma, the most common and deadly form of brain tumor. In findings published May 27 in Science Translational Medicine, the researchers suggest that a transporter known as SXC is responsible for boosting levels of glutamate in the brains of some glioma patients.

28 May 2015

Experimental cancer drug shows promise against incurable paediatric brain cancer

US-Australian drug discovery company, Novogen Limited, in conjunction with Australian paediatric cancer researchers, released key pre-clinical data on experimental cancer drug-candidate, TRXE-009, confirming its potential to become an important new therapy against an incurable paediatric brain cancer called DIPG (diffuse intrinsic pontine glioma).

8 May 2015

Oncologists need to screen tumor patients for depression

Because depression in brain cancer patients is a common but often overlooked condition, oncologists should regularly screen tumor patients for depression, according to an article in the current issue of CNS Oncology. The journal is published by Future Medicine, an imprint of Future Science Group.

30 Apr 2015

Neuro-oncology researchers identify mechanism responsible for tumor cell invasion in glioblastoma

A neuro-oncology research team at Dartmouth's Norris Cotton Cancer Center, led by the Director Mark A. Israel, MD with first author Gilbert J. Rahme, PhD, recently identified the transcription factor Id4 as a suppressor of tumor cell invasion in glioblastoma.

9 Apr 2015

Study suggests possibility of developing personalized treatments for brain cancer

DNA mutations can cause cancer but in some cases, more mutations may mean a better prognosis for patients. A Yale-led comprehensive genomic analysis of more than 700 brain tumors has revealed one such subtype of the most malignant brain tumor, called glioblastoma, or GBM. This subtype possesses thousands of tumor-specific DNA errors or mutations instead of dozens observed in most glioblastoma cases. It is also associated with longer survival.

8 Apr 2015

2015 Minds Matter event raises funds to support brain tumor research

One day in 2009, Maria Nijim's father got behind the wheel of his car and realized he couldn't see out of one eye. An MRI showed a tumor and then surgery confirmed a devastating diagnosis – glioblastoma – the most aggressive type of brain tumor.

25 Mar 2015

Study describes the dual role of microRNA during hepatitis C infection

In the battle between a cell and a virus, either side may resort to subterfuge. Molecular messages, which control the cellular machinery both sides need, are vulnerable to interception or forgery.

13 Mar 2015

Researchers one step closer to understanding development of glioblastoma

Glioblastomas are a highly aggressive type of brain tumor, with few effective treatment options. Moffitt Cancer Center researchers are one step closer to understanding glioblastoma development following the identification of a key protein signaling pathway involved in brain tumor stem cell growth and survival.

26 Feb 2015

First comprehensive maps and analyses of human epigenomes revealed

Two dozen scientific papers published online simultaneously on Feb. 18, 2015 present the first comprehensive maps and analyses of the epigenomes of a wide array of human cell and tissue types. Epigenomes are patterns of chemical annotations to the genome that determine whether, how, and when genes are activated.

18 Feb 2015

St. Luke’s offers Frameless Stereotactic Radiosurgery for treatment of brain tumors

Some treatments for brain and spine tumors traditionally have involved restraining a patient with a heavy immobilization device and pins that pierce the skin and embed into the skull to ensure the accuracy and precision of a treatment. Doctors say the pins can add considerable anxiety.

20 Jan 2015

UT Southwestern researchers find new potential target for halting tumor growth

UT Southwestern Medical Center researchers have discovered that brain tumors are capable of burning acetate for fuel, providing a new potential target for halting tumor growth.

19 Dec 2014

Research finding could lead to new therapies for malignant glioma

Targeted therapies are a growing and groundbreaking field in cancer care in which drugs or other substances are designed to interfere with genes or molecules that control the growth and survival of cancer cells. Now, scientists at Virginia Commonwealth University Massey Cancer Center and VCU Institute of Molecular Medicine (VIMM) have identified a novel interaction between a microRNA and a gene that could lead to new therapies for the most common and deadly form of brain tumor, malignant glioma.

12 Dec 2014

Henry Ford Hospital recruits patients to participate in brain cancer clinical trial

Henry Ford Hospital today announced that it is actively recruiting patients to participate in a clinical trial taking place at the Hermelin Brain Tumor Center which is showing promising results in patients with brain cancer.

8 Dec 2014

Research shows that immune checkpoint inhibitors may work in glioblastoma, brain metastases

New evidence that immune checkpoint inhibitors may work in glioblastoma and brain metastases was presented today by Dr Anna Sophie Berghoff at the ESMO Symposium on Immuno-Oncology 2014 in Geneva, Switzerland.

23 Nov 2014

Study: Chemotherapy following radiation therapy improves survival in adults with low-grade gliomas

A chemotherapy regimen consisting of procarbazine, CCNU, and vincristine (PCV) administered following radiation therapy improved progression-free survival and overall survival in adults with low-grade gliomas, a form of brain cancer, when compared to radiation therapy alone.

17 Nov 2014

UH's Neurological Institute designated as Gold Center of Excellence

The Neurological Institute at University Hospitals has been designated as a Gold Center of Excellence (COE) and featured as a top performing center by NeuStrategy, Inc., a Chicago consulting firm providing strategic support to neuroscience, oncology and orthopaedic service providers.

23 Oct 2014